What clinical decision would TP53 prime editing support?

Actionability check: is TP53 prime editing intended as a treatment itself, or as a functional test that changes therapy selection in colorectal cancer? Demonstrating precise sequence correction or restored tumor-suppressor function would establish biological activity, not patient benefit. Translation would require eligibility defined across TP53 variants and tumor contexts, a clinically credible comparator, and endpoints capturing durable tumor control, toxicity, and escape after editing. The key denominator is all screened tumors, including those that cannot be edited efficiently or specifically—not only successfully edited models.